Federal prosecutors allege Michael McMillan built a clinician-centered sales network that offered skin substitutes without upfront costs, promised providers substantial shares of successful government reimbursements, and linked product use to disputed pricing disclosures and representative commissions.
WASHINGTON, DC — Federal prosecutors allege Las Vegas businessman Michael McMillan recruited physicians, podiatrists, nurse practitioners, and other medical providers whose authority to select, apply, and bill skin-substitute products became the essential clinical gateway for a nationwide reimbursement operation.
The indictment says McMillan and companies operating collectively as Protectus encouraged those clinicians to use designated wound-care products by offering an arrangement under which practices allegedly retained thousands of dollars whenever Medicare, TRICARE, or CHAMPVA approved a related claim.
Prosecutors contend the model connected three decisions ordinarily expected to remain independently justified: provider recruitment influenced product use, product use generated government claims, and successful claims determined how reimbursement was divided among clinicians, Protectus, and sales representatives.
The government does not merely accuse McMillan of selling medical supplies to professional customers; its theory alleges he and Protectus used provider profit guarantees, reimbursement-dependent invoices, billing assistance, and inflated acquisition-price disclosures to turn clinical product selection into disputed federal revenue.
McMillan has not been convicted, every accusation remains unproven, and neither an indictment nor an enforcement announcement establishes that any provider, employee, representative, company, treatment decision, or skin-substitute application violated federal law during the charged period.
Clinicians Allegedly Provided the Necessary Billing Access
Physicians, podiatrists, and nurse practitioners mattered to the alleged operation because Protectus could distribute products and explain reimbursement economics, but licensed providers possessed the patient relationships, clinical authority, and billing access required to turn those materials into government-paid claims.
The official federal indictment against Michael McMillan alleges that he used related companies and sales representatives to recruit clinicians who would apply Protectus products to patients and submit reimbursement requests through government healthcare benefit programs.
Under the prosecution’s theory, clinicians were not peripheral purchasers within an ordinary supply chain, because each participating practice allegedly determined whether a beneficiary received a skin substitute, documented the encounter, presented the claim, collected payment, and transferred an agreed percentage to Protectus.
That sequence placed provider judgment at the center of the alleged conduct, while also giving prosecutors a basis for arguing that financial rewards could influence product selection even when medical charts, claim certifications, and patient care remained formally controlled by licensed professionals.
What Prosecutors Mean by Targeted Products
The phrase targeted products should not be understood as identifying one named brand or asserting that every skin substitute distributed by Protectus was unsuitable, because the indictment broadly describes various cellular or tissue-based wound products offered through McMillan’s interconnected companies.
Prosecutors instead focus upon Protectus products as a commercial category within the alleged arrangement, contending that representatives recruited clinicians specifically to use products supplied by McMillan’s entities and then explained the profit each successfully reimbursed application could generate.
Product targeting therefore refers primarily to directing provider business toward Protectus inventory rather than proving that one material always produced the highest available payment, although reimbursement value allegedly shaped the economic incentives surrounding every approved claim.
The distinction matters because clinical appropriateness, claim eligibility, acquisition-price accuracy, and kickback liability present separate factual questions, meaning evidence about one product or provider cannot automatically establish wrongdoing across every transaction in the government’s aggregate totals.
Skin Substitutes Carry Product-Specific Reimbursement Values
Skin substitutes, sometimes described as cellular or tissue-based products, allografts, or wound grafts, are placed over open wounds to support closure or tissue growth when a patient’s condition and treatment history satisfy applicable clinical and reimbursement requirements.
Government programs generally calculate product reimbursement using a price assigned per square centimeter, making the selected material, package dimensions, wound measurements, amount applied, amount discarded, treatment frequency, and supporting documentation potentially important to the resulting claim value.
That pricing structure means a clinician’s product choice can materially change reimbursement even when two products serve broadly similar wound-care purposes, creating legitimate reasons for careful selection while also making high-value utilization especially attractive to commercially motivated intermediaries.
Prosecutors have not established that McMillan instructed every clinician to choose the single most expensive available product, but they allege his business model rewarded repeated use of Protectus materials through provider margins calculated directly from government payments.
Medical Necessity Remained a Separate Requirement
Medicare, TRICARE, and CHAMPVA cover eligible skin-substitute treatment only when program requirements are satisfied, including medical-necessity standards that generally demand appropriate wounds, supporting documentation, qualifying treatment histories, and clinically defensible product applications for covered beneficiaries.
The McMillan indictment emphasizes alleged kickbacks and price misrepresentations more heavily than it emphasizes individualized findings that every treatment was medically unnecessary, making it inaccurate to assume that each patient lacked a qualifying wound or received no clinical benefit.
Even medically useful treatment can produce a legally challenged claim when prosecutors prove that prohibited remuneration induced the order or material pricing information was knowingly misstated, because federal payment eligibility encompasses more than whether a product physically reached a wound.
Conversely, the government cannot prove the charged conspiracies merely by showing expensive products were selected, since prosecutors must connect provider recruitment, reimbursement sharing, claim representations, McMillan’s knowledge, and the alleged unlawful purpose through admissible evidence.
No Upfront Cost Allegedly Changed Provider Incentives
Protectus allegedly supplied participating practices with skin-substitute products without requiring payment before application, allowing providers to treat patients and seek government reimbursement without committing their own money to inventory that might later generate a denied claim.
When Medicare or another government program denied reimbursement, prosecutors say Protectus generally did not invoice the provider, effectively shifting the product-cost risk away from the practice while tying the provider’s financial obligation to a successful public payment.
When reimbursement arrived, Protectus allegedly charged only about 60 percent to 70 percent of the collected amount, leaving the practice with approximately 30 percent to 40 percent and potentially thousands of dollars from each approved product claim.
The indictment characterizes that retained share as an illegal kickback disguised as a rebate or discount, while defense counsel may argue that delayed billing, customer credit, contingent pricing, commercial risk allocation, and lawful discounts require closer legal and factual analysis.
Provider Profit Allegedly Grew with Reimbursement
Because the provider’s retained amount allegedly represented a percentage of reimbursement rather than a fixed dollar discount established before treatment, larger government payments could generate correspondingly larger practice profits under the arrangement described by federal prosecutors.
That alleged proportionality is central to the government’s clinician-recruitment narrative, since a percentage-based return could make product utilization financially attractive beyond ordinary professional compensation for evaluating wounds, applying materials, documenting care, and managing follow-up treatment.
Prosecutors will likely argue that the guaranteed margin created a direct incentive to choose Protectus products and generate reimbursable applications, while the defense can examine whether providers independently selected appropriate care and understood their pricing terms as lawful commercial discounts.
The legal question will not be whether physicians or podiatrists may earn income from wound care, because legitimate professional fees remain ordinary, but whether McMillan knowingly offered additional remuneration to induce federally reimbursed product orders or recommendations.
Sales Representatives Allegedly Recruited the Providers
The indictment says McMillan hired sales representatives to locate and recruit medical providers, placing those representatives between Protectus and the clinicians whose patient access, ordering authority, treatment decisions, and billing privileges could generate federal reimbursement for company products.
Representatives allegedly explained the provider profit-sharing arrangement and described how much a practice would retain for each successfully reimbursed skin-substitute claim, making expected financial return part of the recruitment presentation rather than an incidental consequence discovered after treatment.
Their own compensation allegedly depended upon reimbursement generated by the clinicians they recruited, because Protectus purportedly paid commissions only after practices received government money and transferred the company’s 60-percent-to-70-percent share through corresponding invoices.
Prosecutors estimate approximately $27 million went to sales representatives, an allegation that portrays the recruitment network as financially synchronized with provider utilization, claim success, practice payments, and Protectus collections throughout the asserted reimbursement chain.
The Indictment Identifies Five Providers by Letter
The charging document describes five medical providers without publishing their names, identifying one Arlington physician, three podiatrists connected with Santa Monica, McKinney, and Payson, and one Dallas nurse practitioner within examples supporting the alleged conspiracies.
Those professional categories help explain the headline’s focus on physicians and podiatrists, although the presence of a nurse practitioner shows prosecutors describe a wider network of licensed clinicians rather than one specialty operating within a single community.
The providers’ anonymity also requires restraint, because the indictment charges McMillan while describing other known and unknown participants, and public reporting should not speculate about identities, licensing histories, charging prospects, cooperation agreements, or individual knowledge without verified records.
Each clinician could have different contracts, communications, clinical rationales, billing practices, patient populations, financial arrangements, and defenses, so the government’s aggregate theory alone cannot establish that every provider shared McMillan’s alleged criminal intent.
A March 2024 Meeting Illustrates the Recruitment Pitch
During a meeting described in the indictment, McMillan allegedly told one podiatrist that Protectus offered medical providers an average 35-percent rebate and illustrated the arrangement using hypothetical monthly Medicare collections of approximately $180,000.
Under that illustration, the podiatrist could allegedly retain approximately $63,000 from those monthly claims, a calculation prosecutors may present as evidence that provider earnings were deliberately used to encourage utilization of Protectus skin-substitute products.
The same meeting allegedly included McMillan’s statement that he reviewed Medicare claims to ensure Protectus products were billed above what providers actually paid, connecting the recruitment economics with the government’s separate accusation involving inflated acquisition-price reporting.
Defense lawyers may challenge the witness account, context, terminology, completeness, commercial meaning, or legal interpretation of that meeting, while prosecutors must authenticate the evidence and demonstrate that the presentation furthered the charged agreements rather than a lawful sales discussion.
Product Delivery Followed the Alleged Pitch
Shortly after that meeting, Protectus allegedly delivered twelve skin-substitute products to the podiatrist without upfront payment, creating a concrete transaction prosecutors can use to compare the earlier profitability discussion with later applications, claims, reimbursements, denials, and invoices.
The practice later reported that Medicare paid approximately $9,024 on one claim and denied another, after which a Protectus employee allegedly offered to help resolve the denial and requested the payment information needed for invoicing.
Protectus then issued an invoice for approximately $5,865.60, representing 65 percent of the paid claim and leaving the provider with 35 percent, an arithmetic result closely matching the alleged rebate McMillan described during recruitment.
For prosecutors, that chronology links sales presentation, free inventory, provider use, Medicare adjudication, billing support, percentage-based invoicing, and practice profit, while the defense can challenge whether the sequence proves illegality rather than a consistently administered commercial agreement.
Billing Assistance Allegedly Helped Claims Produce Revenue
McMillan and Protectus personnel allegedly billed on behalf of providers or assisted providers with claims, giving the companies a role in converting clinician product use into program reimbursement instead of limiting their activity to inventory delivery and later collection.
In the podiatrist example, a Protectus employee allegedly identified missing acquisition-price information in Box 19 and recommended resubmitting the denied claim with information contained on a spreadsheet, demonstrating the operational importance of claim-level assistance within the alleged model.
Vendors may lawfully help customers navigate coding, coverage, documentation, and administrative denials, so billing support alone does not prove fraud without evidence that someone knowingly supplied or encouraged materially false information.
The prosecution must therefore establish what Protectus personnel knew, which figures they instructed providers to report, who certified each submission, why the information was inaccurate, and whether the disputed representations affected government payment decisions.
Acquisition Price Allegations Connect Use with Payment
The indictment says providers were required to disclose their actual acquisition price, including discounts, rebates, refunds, and other adjustments, through Box 19 when submitting relevant Medicare claims for skin-substitute products used on covered beneficiaries.
Prosecutors allege McMillan and Protectus submitted inflated prices or counseled providers to report figures exceeding their effective costs, thereby preventing Medicare from seeing the reimbursement-dependent reductions that allegedly left practices with substantial retained shares.
That theory turns pricing disclosure into the bridge between clinician product selection and federal loss, because the government contends claims were paid using materially inaccurate economic information while participating practices and Protectus divided the resulting reimbursement.
Defense counsel may dispute whether the invoicing formula changed acquisition price, whether claim instructions were sufficiently clear, whether particular adjustments required disclosure, whether providers controlled final entries, and whether any alleged error was knowing or material.
The Money Flow Allegedly Rewarded Every Recruitment Layer
Prosecutors say government programs paid approximately $268 million on the challenged claims, medical providers retained approximately $94 million, and Protectus received approximately $174 million after practices paid percentage-based invoices tied to successful reimbursements.
The representative payments should not be added as an independent fourth share above $268 million, because the indictment describes approximately $27 million in commissions as downstream compensation paid from Protectus collections after providers transferred company portions.
An NBC 5 Dallas-Fort Worth report examining the unsealed court filings similarly described providers retaining 30 percent to 40 percent, representatives receiving approximately $27 million, and McMillan’s companies collecting the remaining reimbursement through the alleged kickback structure.
Those aggregate numbers make the prosecution’s theory understandable, but they cannot replace provider-specific and claim-specific proof concerning medical use, pricing, billing, remuneration, program eligibility, McMillan’s participation, and the knowledge required for each charged offense.
Reimbursement Volume Allegedly Drove Corporate Growth
The alleged conduct lasted from approximately May 2019 through at least February 2026, giving investigators nearly seven years of claims, invoices, bank transfers, commission reports, communications, contracts, and product records to test reimbursement-linked growth.
If clinical recruitment produced recurring applications and corresponding payments, each new provider could expand the system beyond one territory while allowing Protectus to scale through the practitioner’s existing patients, billing credentials, referral relationships, and wound-care operations.
That scalability explains why provider acquisition may matter more than conventional consumer advertising in a reimbursed medical market: one recruited clinician could generate numerous product claims, while one sales representative could cultivate multiple practices across different jurisdictions.
The defense may answer that commercial expansion through trained healthcare customers is ordinary, leaving prosecutors to prove that growth resulted from prohibited compensation and fraudulent submissions rather than legitimate demand for clinically useful wound-care products.
Clinical Choice and Financial Choice Allegedly Converged
Independent clinical judgment requires providers to select treatment according to patient condition, evidence, safety, expected benefit, alternatives, program rules, and professional standards rather than the personal profit available from one distributor’s preferred product.
Prosecutors will likely argue that a guaranteed percentage of reimbursement created a competing motive that could steer those decisions toward Protectus products, especially when the practice bore no upfront cost and owed nothing after a denied claim.
The defense can still contend that financial terms did not determine medical care, especially where records document appropriate wounds, conservative treatment failures, measured applications, favorable outcomes, and independent provider reasoning supporting the selected product.
Jurors may therefore need to distinguish evidence of economic opportunity from proof of corrupted judgment, recognizing that profitability can coexist with lawful treatment while also considering whether compensation was deliberately offered to induce federally reimbursed orders.
False Claims Do Not Necessarily Mean Products Were Never Used
Healthcare claims can be considered false for several different reasons, including nonexistent treatment, medical necessity failures, inaccurate quantities, misleading diagnoses, hidden kickbacks, ineligible providers, or material misrepresentations concerning price and other payment conditions.
The McMillan allegations focus on remuneration and acquisition-price reporting, so responsible coverage should not claim that every product was missing, every wound was fabricated, every application was unnecessary, or every beneficiary received worthless treatment.
Prosecutors can nevertheless argue that physically delivered products generated ineligible claims when illegal inducements procured their use or inflated price information affected reimbursement, while defense lawyers can challenge both the legal theory and the evidence supporting particular submissions.
This distinction protects patients and clinicians from unsupported generalization while preserving the government’s allegation that a genuine medical item can become part of fraud when its selection, pricing, billing, or payment is intentionally corrupted.
The Charges Require Proof Beyond Recruitment
Count One charges conspiracy to commit healthcare fraud, requiring prosecutors to prove McMillan knowingly joined an agreement involving materially false or fraudulent claims rather than merely operating companies that sold products to medical practices receiving public reimbursement.
Count Two charges a conspiracy to defraud the United States and offer or pay healthcare kickbacks, focusing upon alleged remuneration intended to induce orders, purchases, recommendations, or arrangements involving items reimbursable by federal healthcare programs.
Counts Three through Nine concern seven monetary transactions exceeding $10,000 in allegedly criminally derived property, including real estate, two luxury vehicles, and a private aircraft, each requiring transaction-specific evidence concerning source and McMillan’s knowledge.
Provider recruitment supplies important context for the two alleged conspiracies, but prosecutors must still establish agreement, intent, falsity, materiality, remuneration, causation, and any additional statutory elements applicable to the nine separate counts the grand jury returned.
Documents Could Reveal How Providers Were Selected
Recruitment lists, territory plans, sales presentations, emails, text messages, product catalogs, commission spreadsheets, customer agreements, and reimbursement reports could show whether representatives targeted clinicians because of specialty, beneficiary volume, billing capacity, geographic reach, or expected claim profitability.
Investigators may compare the timing of provider recruitment with subsequent product deliveries and reimbursement growth, testing whether new relationships produced abrupt utilization increases, repeated percentage splits, uniform Box 19 entries, or concentrated use of particular Protectus products.
Defense experts may identify lawful explanations involving new wound-care programs, expanded patient access, changing coverage policies, product availability, improved outcomes, distributor credit, or ordinary sales growth that complicate any inference drawn from numerical patterns alone.
The evidentiary contest will likely combine broad analytics with individual communications, because aggregate correlations can reveal patterns while contemporaneous records and witness testimony explain what participants understood when they made clinical and commercial decisions.
Provider Records Could Support Competing Narratives
Medical charts may show wound dimensions, diagnoses, infection risks, prior treatments, vascular assessments, photographs, product quantities, discarded material, response to therapy, and follow-up care, allowing experts to evaluate whether each documented application had a defensible clinical basis.
Claims records may separately show billed product codes, square centimeters, acquisition-price disclosures, dates of service, reimbursement amounts, denials, corrections, and resubmissions, enabling both sides to compare clinical documentation with the economic representations presented to federal programs.
Bank statements and invoices can then show whether provider obligations arose before treatment or only after reimbursement, how much each practice retained, when Protectus collected, and whether representative commissions followed the same successful claims.
When these records align, prosecutors may argue they expose an integrated inducement system, while defense counsel may use inconsistencies, legitimate value, isolated errors, or provider independence to resist treating every transaction as part of one fraudulent plan.
Uncharged Providers Should Not Be Presumed Guilty
The indictment’s descriptions of medical providers as participants within alleged events do not establish convictions, and the absence of publicly stated charges against a clinician does not reveal whether investigators view that person as a witness, subject, target, victim, or cooperating participant.
Individual providers may have received incomplete information, relied upon billing staff, misunderstood pricing requirements, returned payments, corrected claims, sought legal advice, rejected proposed terms, or possessed evidence materially distinguishing their conduct from the government’s general account.
Public identification based upon speculation could damage professional reputations, expose patient confidentiality, interfere with proceedings, and incorrectly merge people whose knowledge and conduct may differ, making careful attribution especially important throughout pretrial litigation.
The presumption of innocence applies to McMillan, while basic fairness also requires avoiding unsupported conclusions about unnamed clinicians, representatives, employees, beneficiaries, and companies that have not received an opportunity to contest public allegations.
The Defense Has Multiple Paths to Challenge Intent
McMillan’s lawyers can argue the provider arrangements represented lawful discounts, deferred payment, consignment, financing, or risk-sharing rather than remuneration intended to induce orders, while also disputing whether any available safe-harbor requirements or disclosure duties applied as prosecutors contend.
They may challenge McMillan’s personal knowledge of claim entries, employee communications, provider billing decisions, representative statements, and individual contracts, emphasizing that corporate ownership does not automatically prove authorization of every act across six related entities.
The defense can also contest witness credibility, document authenticity, search procedures, data completeness, expert methodology, price calculations, reimbursement causation, account tracing, legitimate product value, and the government’s decision to aggregate varied providers and transactions.
Most importantly, prosecutors carry the burden throughout, meaning unusual pricing, large reimbursements, high commissions, provider profits, or luxury purchases cannot substitute for proof beyond a reasonable doubt concerning every required element of each count.
Compliance Lessons Extend Beyond the McMillan Case
Wound-care manufacturers, distributors, practices, billing companies, and marketing organizations should review arrangements in which providers receive products without upfront payment, owe nothing after denial, and retain fixed percentages of successful government reimbursements after vendor invoicing.
Compliance teams should test whether product selection remains clinically independent, acquisition-price disclosures reflect final economic cost, representatives discuss practice profit, commissions depend upon claim success, and vendors influence information submitted under provider billing credentials.
Organizations should preserve contracts, price sheets, product records, clinical notes, claim forms, reimbursement notices, invoices, commission reports, emails, messages, bank statements, and training materials because ordinary business documents can later establish knowledge, consistency, control, or corrective action.
Independent claim sampling can identify recurring percentage formulas, omitted adjustments, unusual utilization, repeated denials, concentrated product selection, rapid geographic expansion, and representative-driven profitability before questionable practices become embedded across a broader clinical network.
Patients and Public Programs Share the Risk
Chronic wounds can expose older adults, people with diabetes, veterans, military families, and medically fragile patients to infection, hospitalization, amputation, severe pain, and reduced mobility, making access to clinically appropriate advanced treatment genuinely important.
Financial incentives may create patient risk when they influence which product is selected, how much material is applied, how frequently applications occur, or whether practitioners continue treatment beyond a point supported by documented healing and accepted standards.
Improper claims also threaten public programs by directing finite resources toward transactions administrators would reject if they knew about prohibited remuneration or inaccurate pricing, potentially increasing costs while undermining confidence in legitimate wound-care reimbursement.
Enforcement must nevertheless avoid discouraging appropriate treatment, because skin substitutes can benefit qualifying patients and allegations against one distributor should not stigmatize compliant clinicians, responsible manufacturers, or beneficiaries who depend upon advanced wound-care options.
Reputation Can Shift Before Evidence Is Tested
An indictment alleging that physicians and podiatrists were recruited through reimbursement-linked profits can rapidly affect provider relationships, employment, financing, licensing attention, patient confidence, and search results long before discovery, motions, trial, verdicts, or appeals establish final facts.
Organizations facing that imbalance may need disciplined crisis public-relations management that distinguishes allegations from adjudicated conduct, protects confidential health information, corrects verifiable inaccuracies, coordinates authorized statements, and avoids emotional responses that could create additional legal exposure.
Longer-term reputation-rebuilding strategies can document procedural developments, verified compliance reforms, leadership changes, independent audits, and stakeholder responses without concealing material facts or falsely describing an unresolved criminal case as either proven guilt or complete exoneration.
McMillan, Protectus entities, providers, representatives, employees, patients, and third parties occupy different factual positions, making tailored communication important whenever a collective response could imply shared culpability, contradict court filings, compromise defense strategy, or disclose protected information.
The National Takedown Increased Visibility
The McMillan case emerged during the 2026 National Health Care Fraud Takedown, a coordinated federal and state enforcement campaign that announced charges against hundreds of defendants across numerous districts, benefit programs, clinical sectors, and alleged fraud models.
Within the Northern District of Texas, prosecutors announced seven cases involving more than $365 million in alleged fraudulent billing, placing the approximately $268 million Protectus matter at the center of a highly visible regional enforcement narrative.
That broader campaign explains the immediate publicity surrounding McMillan, but accusations involving unrelated cardiology, hospice, laboratory, equipment, or behavioral-health defendants cannot establish anything about the evidence supporting his wound-care charges against McMillan in federal court.
Jurors must evaluate the Protectus allegations independently, without allowing the scale of a national announcement, statements about other schemes, or public anger over healthcare fraud to replace individualized consideration of admissible evidence under governing federal criminal standards.
What Happens Next in Federal Court
Pretrial proceedings may examine claim data, provider communications, sales presentations, product records, pricing rules, Box 19 disclosures, reimbursement reports, commission calculations, corporate accounts, search procedures, witness credibility, and statements prosecutors attribute directly to McMillan.
The government will seek to show that clinician recruitment was a deliberate mechanism for generating Protectus product claims, while the defense will likely separate lawful commercial outreach from any provider’s independent treatment and billing decisions.
Expert testimony may address wound-care standards, skin-substitute pricing, Medicare claim requirements, commercial discounts, federal kickback restrictions, statistical patterns, financial tracing, and whether disputed information could have influenced reimbursement decisions for the competing parties.
Any eventual restitution, forfeiture, or sentence would depend upon sustained counts, proven loss, legitimate value, recovered property, McMillan’s role, criminal history, guideline findings, victim evidence, and individualized judicial discretion rather than headline totals alone.
No final outcome can responsibly be predicted from the indictment, because discovery, evidentiary rulings, witness cooperation, plea discussions, factual stipulations, trial testimony, jury findings, post-trial motions, and appeals may substantially alter the case.
Until jurors return verdicts or another lawful resolution concludes the prosecution, Michael McMillan remains presumed innocent, every clinician-related allegation remains subject to adversarial testing, and the government must prove that recruitment, product use, billing, and reimbursement formed knowing criminal conspiracies.
